Base-based Halogenation Modification Service
Introduction
Typically, nucleotide modification is achieved by halogenation at the base of a nucleoside or nucleotide to change its chemical structure and properties. In this step, halogen atoms, such as bromine or iodine, are introduced onto the bases of nucleosides or nucleotides to form halogenated groups. Such modifications change the charge distribution, chemical properties, and spatial distribution of the bases. A common method is to use a specific reagent, such as iodic acid or trichloroacetic acid, to react with the base to form a halogenated compound. Base-based halogenation modification has a wide range of applications in DNA sequencing, DNA methylation analysis, and DNA modification studies. Modifying the properties of these molecules can help scientists better understand the functional mechanisms of these molecules in biological processes such as gene expression and protein synthesis. In addition, it can be used to explore and study the role of disease-related genes and to develop novel drugs.
Key Technologies
Our expertise in base-based halogenation is built upon a foundation of cutting-edge synthetic chemistry and enzymatic biocatalysis. We employ a dual-pronged technological approach to achieve high-purity, site-specific halogenation.
- Chemical Synthesis
The cornerstone of our service involves highly controlled chemical reactions, such as the use of N-halosuccinimides, to introduce halogens onto the base moiety of nucleoside and nucleotide precursors. This method offers unparalleled versatility and precision, allowing for the halogenation of various purine and pyrimidine bases with a high degree of regioselectivity. The process is meticulously optimized to ensure efficient halogen incorporation while preserving the integrity of the nucleoside structure.
- Enzymatic Biocatalysis
In addition to chemical methods, we harness the power of engineered enzymes for late-stage modifications. This biocatalytic approach allows for the highly specific and stereoselective halogenation of complex substrates, offering a sustainable and efficient alternative to traditional chemical routes. Our proprietary enzymatic systems are tailored to install halogen atoms at unactivated sites, providing a powerful tool for rapid diversification of compound libraries and overcoming synthetic challenges.
Halogen-Engineered Bases: Stability by Design.
CD BioGlyco has established a Glyco™ Synthesis Platform to provide Custom Sugar-nucleotides Synthesis services to our clients. We provide not only an Oligonucleotide Modification Service but also Nucleoside & Nucleotide Modification Service. We have advanced synthesis instruments and experienced technicians to ensure the quality of base-based halogenation modification. The details of our experiments are as follows:
- The first step is the preparation of nucleosides or nucleotides containing bases. To protect specific functional groups, a protecting group is introduced at the base of the nucleotide before halogenation modification to prevent it from being unnecessarily interfered with in subsequent reactions.
- Subsequently, we perform reactions of halogen compounds with starting materials in appropriate solvents and at lower temperatures to introduce halogens to specific sites in the nucleotide. Our commonly used halogen compounds include bromoacetyl and sulfonyl bromide. Then we control the stereoselectivity of halogen substitution according to your specific requirements. This is usually achieved by introducing chiral ligands or selective catalysts.
- Finally, the protecting groups were removed and the products were purified and characterized.
Workflow
- Preparation of Starting Materials
Nucleosides or nucleotides containing the target bases are prepared for modification.
- Protection of Functional Groups
Protecting groups are introduced at specific base sites to prevent unwanted side reactions during halogenation.
- Halogenation Reaction
Halogen compounds (e.g., bromoacetyl, sulfonyl bromide) react with the protected nucleosides/nucleotides in appropriate solvents at controlled (lower) temperatures to introduce halogen atoms (e.g., Br, I) onto specific sites of the base.
- Stereoselectivity Control
The stereoselectivity of the halogen substitution is controlled, often using chiral ligands or selective catalysts, to achieve the desired configuration as specified by the client.
- Deprotection
The protecting groups added in step 2 are removed from the halogenated product.
- Purification & Characterization
The final halogenated nucleoside/nucleotide product is purified and characterized to confirm its identity, purity, and structure.
Publication Data
DOI.: 10.1039/d5cb00077g
Journal: RSC Chemical Biology
IF: 3.1
Published: 2025
Results: This comprehensive review systematically examines the role of halogenation in nucleic acids, emphasizing its dual significance in structural biology and supramolecular chemistry. The authors explore how incorporating halogens (Br, I) into DNA/RNA bases—historically used for crystallographic studies—fundamentally alters nucleic acid stability, conformation, and molecular recognition. Key findings reveal that halogen atoms participate in non-covalent halogen bonding (HalB), which stabilizes non-canonical structures (e.g., Z-DNA, G-quadruplexes) and modulates protein-nucleic acid interactions. The review critically analyzes halogenation-induced DNA damage (e.g., 5-halocytosine, 8-haloguanine) during inflammation, linking it to mutagenesis and cancer progression. Additionally, the authors highlight HalB's utility in designing supramolecular assemblies and propose halogenated peptide nucleic acids (PNAs) as novel tools for sequence-specific recognition. By integrating experimental and computational insights, this work underscores halogen bonding as a pivotal force in nucleic acid chemistry, offering strategies for therapeutic development and structural engineering.
Applications
- Nucleosides & nucleotide modifications are widely used in modern genomics and transcriptomics research, providing essential tools for understanding biological processes and studying diseases.
- Nucleotide modification technology provides a new way for the design and development of antiviral drugs and is a powerful tool for research on viral infections.
- Modified nucleotides can be used as probes for specific sequences for gene detection and mutation analysis.
Advantages of Us
- We have a stock of high-quality raw materials that are strictly screened and verified to meet international standards and quality requirements.
- We work closely with our clients to understand their specific requirements and provide a one-to-one customized service.
- Our technicians have a wide range of knowledge and expertise, with extensive hands-on experience in a variety of fields.
Frequently Asked Questions
Associated Services
Our base-based halogenation modification enables precise halogen introductions (F, Cl, Br, I) to optimize nucleic acid stability, binding specificity, and metabolic resilience for applications like aptamer engineering or antisense therapeutics. To extend this atomic-level precision into functional glycan interaction mapping, we offer Glycomics Profiling with Microarray—a multiplexed platform for high-throughput interrogation of glycan-mediated interactions across biological systems. This technology decodes glycan-binding specificities through:
- Phyto-glycan Microarray Screening Service
- Microbe-focused Glycan Array Screening Service
- Mammalian Glycomics Microarray Scanning Service
- Microarray-based Glycoproteomics Service
- Lectin Binding Protein Microarray Services
CD BioGlyco focuses on providing high-quality base-based halogenation modification services for nucleosides and nucleotides. Through precise synthetic processes and advanced technology, we selectively achieve base halogenation modification and provide custom solutions for our clients. If you are interested in our services, please feel free to contact us for more details.
Reference
- Nicolau, C., et al. Halogenation of nucleic acid structures: from chemical biology to supramolecular chemistry. RSC Chemical Biology. 2025. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




